Initial Slovenian experience with MitraClip therapy
- 51 Downloads
MitraClip is a percutaneous mitral repair technology increasingly used for high surgical risk patients with primary or secondary mitral regurgitation. We describe initial Slovenian experience with MitraClip and discuss the importance of identifying the suitable candidates for this procedure.
We retrospectively analyzed the first 10 patients (mean age 75.6 ± 6.9 years, logistic Euroscore 28.4 ± 10.9%) with severe and moderate to severe mitral regurgitation (8 secondary, 1 primary and 1 mixed etiology) who underwent a MitraClip procedure between January 2015 and February 2017.
Acute reduction of mitral regurgitation was achieved in all but one patient (90%). There were no periprocedural mortalities and at short to mid-term follow-up (median 12 months, interquartile range 3–15 months). In eight patients improvement of functional class was observed at discharge. No functional improvement was achieved in a patient with advanced ischemic cardiomyopathy, and in a patient with degenerative mitral disease in whom the MitraClip procedure had failed necessitating mitral valve surgery. One patient experienced late leaflet detachment and was effectively managed with a second MitraClip procedure. There were two vascular complications at the access site and one percutaneous closure of an iatrogenic atrial septal defect.
Our initial experiences with a small number of patients indicate that percutaneous mitral repair with MitraClip is a feasible and safe method in high-risk patients. Special attention should be paid to careful patient selection including detailed echocardiographic evaluation of mitral valve anatomy, technical performance and final result, particularly at the beginning of the learning curve in order to reduce the rate of serious complications.
KeywordsMitraClip Mitral regurgitation Percutaneous mitral valve repair Echocardiography Mitral anatomy
Compliance with ethical guidelines
Conflict of interest
J. Ambrožič, M. Cvijič, M. Bervar, Š. Mušič, and M. Bunc declare that they have no competing interests.
This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent was obtained from all patients identifiable from images or other information within the manuscript.
- 2.ESC Scientific Document Group, Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–91.Google Scholar
- 3.Scientific Document Committee of the European Association of Cardiovascular Imaging, Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013;14:611–44.CrossRefGoogle Scholar
- 6.Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1‑year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62(12):1052–6.CrossRefPubMedGoogle Scholar
- 11.Ambrozic J, Toplisek J, Knezevic I, Bunc M, Stajer D. Chronic ischemic mitral regurgitation—a diagnostic and therapeutic challenge. Slov Med J. 2014;83(1):54–69.Google Scholar
- 12.Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) (COAPT). Available at: https://clinicaltrials.gov/ct2/show/NCT01626079. Accessed November 10, 2017.
- 13.A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation (RESHAPE-HF). Available at: https://clinicaltrials.gov/ct2/show/NCT01772108. Accessed November 10, 2017.
- 15.A Multicenter, Randomized, Controlled Study to Assess Mitral vAlve reconsTrucTion for advancEd Insufficiency of Functional or iscHemic ORigiN (MATTERHORN). Available at: https://clinicaltrials.gov/ct2/show/NCT02371512. Accessed November 10, 2017.